Tag Archives: Ritu Baral

Cowen & Co. Keeps a Buy Rating on SAGE Therapeutics (SAGE)

Cowen & Co. analyst Ritu Baral maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $96.00. The company’s shares closed last Monday at $61.02, close to its 52-week low of $56.50.

ACADIA Pharmaceuticals (ACAD) Receives a Rating Update from a Top Analyst

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $66.00. The company’s shares closed last Monday at $44.28, close to its 52-week

Cowen & Co. Maintains a Buy Rating on Alnylam Pharma (ALNY)

In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $120.00. The company’s shares closed last Monday at $92.73, close to its 52-week

Allena Pharmaceuticals (ALNA) Receives a Buy from Cowen & Co.

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Allena Pharmaceuticals (ALNA – Research Report). The company’s shares closed last Monday at $1.64, close to its 52-week low of $1.55. According to TipRanks.com,

Cowen & Co. Sticks to Its Buy Rating for Milestone Pharmaceuticals (MIST)

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Milestone Pharmaceuticals (MIST – Research Report), with a price target of $32.00. The company’s shares closed last Monday at $18.00. According to TipRanks.com, Baral

Cowen & Co. Reaffirms Their Buy Rating on Aptinyx (APTX)

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Aptinyx (APTX – Research Report). The company’s shares closed last Monday at $3.40, close to its 52-week low of $2.61. According to TipRanks.com, Baral